Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated ...
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...
India and France have struck a deal to revise their 1992 treaty which will halve the tax on dividends paid by Indian units to French parents, potentially saving millions for companies with major ...
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...
TipRanks on MSN
Sanofi’s dupilumab study completion: Implications for asthma treatment and market impact
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi recently completed a study titled ‘National, Multicenter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback